This report was first published by Endpoints News. To see the original version, click here
Genentech’s shift from one of the largest drug benefit plans to a privately-held entity is expected to save the Roche subsidiary tens of millions of dollars, the company’s CEO said.
Genentech CEO Ashley Magargee exclusively told Endpoints News that the move could save about $70 million through 2028. Genentech is at least the second large pharma to sign onto Rightway, a pharmacy benefit startup founded in 2017.
您已阅读16%（502字），剩余84%（2705字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。